Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > I’m bullish.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Comment by Inthepezon Aug 20, 2021 1:14pm
118 Views
Post# 33740339

RE:RE:RE:I’m bullish.

RE:RE:RE:I’m bullish.

"So when I said 5x ALT levels is extremely dangerous, I was speaking on behalf of an average retail investor. Why do you think this stock dropped 70% overnight? Because that’s what they thought, and since this stock has barely recovered, that’s still their primary mindset. They are worried about this setback and that’s why they’re not buying. To make matters worse, the insiders aren’t buying either which gives them even more confirmation (and please don’t try and tell me the tiny little insider buy orders we saw actually meant anything, that was an absolute disgrace)"

Saying that vs “Today's report was the final nail in the coffin” and  “its over. It's not speculation. If the company knew this was all fudd and an overreaction” are 2 different things

Its is an over reaction because trading below $1 is under book value. So if the company goes under today, its still worth ~1.30/share. The retail investor is spooked by anything. Hence why the call to uplist to NASDAQ for institutional support. 

But alas, you're too emotional to understand. Any more pics to share, incel?

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities